Jazz Pharmaceuticals Announce the FDA Acceptance of New Drug Application for JZP-258

Jazz Pharmaceuticals plc announced that the US Food and Drug Administration (FDA) accepted for filing with Priority Review the company’s New Drug Application seeking marketing approval for […]

Jazz Pharmaceuticals Presents Positive JZP-258 Phase 3 Study Data at World Sleep 2019

Jazz Pharmaceuticals plc announced positive data from the Phase 3 study of its investigational medicine, JZP-258, for the treatment of cataplexy and excessive daytime sleepiness in adults […]